Characterization of Metabolic Changes in the Glioma Tumor Tissue Induced by Transient Fasting (ERGO3) — ERGO3

Glioma, Mixed Clinical Trial

Official title:
Characterization of Metabolic Changes in the Glioma Tumor Tissue Induced by Transient Fasting (ERGO3)

Status Active, not recruiting

Clinical Trial Summary

Nutritional interventions such as ketogenic diet (KD) or fasting are currently under evaluation as anti-cancer treatment. In glioma patient cohorts, the feasibility and safety of fasting in addition to antitumor treatment has been shown. However, it is still unclear whether fasting exerts effects on the glioma tumor tissue at all, and whether fasting causes metabolic or immunological changes in the glioma microenvironment that could be exploited therapeutically. Therefore, the central contribution of this study is to characterize metabolic and immunological changes in the glioma tumor tissue induced by a fasting cycle of 72 hours prior to biopsy or resection.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04461938
Study type	Interventional
Source	Goethe University
Contact
Status	Active, not recruiting
Phase	N/A
Start date	August 19, 2020
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05984667` - C-SMART: Cognitive Strategies, Mindfulness, and Rehabilitation Therapy for Patients With Primary Brain Tumors
Completed	`NCT05100173` - Clinical Evaluation of Genetron IDH1 PCR Kit in Glioma Patients
Terminated	`NCT04541225` - Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors	Phase 1